What is the clinical evidence from this study?

Study design: RCT. Population: Atrial Fibrillation. Intervention: Rivaroxaban vs. Warfarin.

What question did this study set out to answer?

This analysis aims to evaluate how the effects of rivaroxaban and warfarin vary based on patients' renal function levels.

March 6, 2017CirculationOpen Access

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin

View Full Paper

Ask AI

Bookmark

Key result

An analysis of the ROCKET AF trial evaluated the consistency of rivaroxaban versus warfarin across baseline creatinine clearance levels, though no quantitative results are reported in the abstract.

Why the study?

Does rivaroxaban compared to warfarin have a consistent treatment effect across different levels of baseline renal function in patients with atrial fibrillation?

Population

Patients with atrial fibrillation from the ROCKET AF study

Comparison

Rivaroxaban vs Warfarin

Design

Cohort

Authors

SLSamuel M. LindnerUniversity of North Carolina at Chapel Hill CFChristopher B. FordyceHeart Failure & Transplant AHAnne S. HellkampElectrophysiology

Discussion

Member takes

Implication

Supports consistent rivaroxaban-warfarin effects across CrCl in AF; leaves open dedicated trials in severe renal impairment.

Key Points

This analysis aims to evaluate how the effects of rivaroxaban and warfarin vary based on patients' renal function levels.
Utilized data from the ROCKET AF trial (NCT00403767) to assess treatment effects based on baseline creatinine clearance (CrCl).
Focused on patients with varying levels of renal function and examined outcomes relating to thromboembolism and bleeding rates.
The treatment effects of rivaroxaban and warfarin were consistent across varying levels of baseline creatinine clearance.
Patients with impaired renal function had higher rates of bleeding and thromboembolism, stressing the importance of careful management in this group.

Study Design

Type

RCT

Structured PICO

Does rivaroxaban compared to warfarin have a consistent treatment effect across different levels of baseline renal function in patients with atrial fibrillation?

Population

Patients with atrial fibrillation from the ROCKET AF study

Intervention

Rivaroxaban

Comparator

Warfarin

Outcome

Consistency of treatment effect (thromboembolism and bleeding) across the full range of baseline creatinine clearance

This analysis evaluates whether the efficacy and safety of rivaroxaban versus warfarin in atrial fibrillation are consistent across different levels of baseline renal function.

Cite This Study

Lindner et al. (2017) conducted an RCT in Atrial Fibrillation. Rivaroxaban vs. Warfarin was evaluated. An analysis of the ROCKET AF trial evaluated the consistency of rivaroxaban versus warfarin across baseline creatinine clearance levels, though no quantitative results are reported in the abstract.

synapsesocial.com/papers/6a58e6318b99c438338085c8 https://doi.org/10.1161/circulationaha.116.024666

Topics

Atrial fibrillation Anticoagulation in AF Persistent AF management

View Full Paper

Ask AI

Bookmark

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Topics

Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider